Abstract
EGFR and HER2 receptors are crucial signaling molecules tyrosine kinase involved in human cancer. Aberrant signaling is associated with a variety of cancers, frequently with poor prognosis. Currently, EGFR and HER2 receptors are being targeted by small molecules, which offer a huge benefit to those patients afflicted by aggressive forms of cancer, improving their prognosis. Both human and canine cancers share molecular, biological, histopathological and clinical similarities, including EGFR and HER2 expression in some forms of cancer. However, despite the use of one tyrosine kinase inhibitor approved to treat canine mastocytoma, canine cancers overexpressed EGFR and HER2 do not yet have targeted therapy, leading to high morbidity and mortality. Targeting EGFR and HER2 receptors in canine cancers using comparative approaches in human cancer could lead to better outcomes.
Highlights
Summaryepidermal growth factor receptor (EGFR) and HER2 receptors are crucial signaling molecules tyrosine kinase involved in human cancer
Cancer is the most important cause of death in dogs worldwide [1,2,3]
As observed in human patients epidermal growth factor receptor (EGFR) and HER2 receptors, tyrosine kinase receptors that play a fundamental role in the control of fundamental transduction and signaling cellular pathways involved in cell survival, cell proliferation, angiogenesis, cell adhesion, cell motility, development, and organogenesis, their dysregulation can result in both development and progression of a variety of tumors [4, 5]
Summary
EGFR and HER2 receptors are crucial signaling molecules tyrosine kinase involved in human cancer. EGFR and HER2 receptors are being targeted by small molecules, which offer a huge benefit to those patients afflicted by aggressive forms of cancer, improving their prognosis. Both human and canine cancers share molecular, biological, histopathological, and clinical similarities, including EGFR and HER2 expression in some forms of cancer. Actualmente, EGFR y HER2 son tratados específicamente a través de pequeñas moléculas inhibidoras, las cuales ofrecen un gran beneficio a aquellos pacientes que padecen formas agresivas de cáncer, y de esta manera su pronóstico mejora. Palabras clave: Cáncer humano, cáncer en veterinaria, EGFR, HER2, inhibidores
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Revista Colombiana de Ciencias Químico-Farmacéuticas
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
